Name: Cyclosporine
Brand: Selleck Chemicals
SKU: S1514
Availability: InStock
Rating: 5 (14 reviews)

Jump to

Quality Control

Batch: Purity: 99.87%

99.87

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase
Other phosphatase Inhibitors	Osunprotafib (ABBV-CLS-484) SHP099 Hydrochloride RMC-4550 SHP099 Batoprotafib (TNO155) GSK2830371 β-Glycerophosphate sodium salt hydrate NSC87877 TPI-1 Suramin sodium salt

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (83.15 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	2%DMSO 1 40%PEG300 2 2%Tween80 3 56%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.000mg/ml (2.49mM)	Taking the 1 mL working solution as an example, add 20 μL of 150 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 20 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 560 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1202.61	Formula	C₆₂H₁₁₁N₁₁O₁₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	79217-60-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	calcineurin phosphatase
In vitro	Cyclosporine induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. This compound's treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. It has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes in activated T cells. This chemical, through formation of a complex with cyclophilin, inhibits the phosphatase activity of calcineurin, which regulates nuclear translocation and subsequent activation of NFAT transcription factors. It also blocks the activation of JNK and p38 signaling pathways triggered by antigen recognition, making CsA a highly specific inhibitor of T cell activation. Its-mediated inhibition of the biliary excretion of MPAG by the Mrp2 transporter is the mechanism responsible for the interaction between this compound and mycophenolate mofetil (MMF). It inhibits biochemical and morphological differentiation of skeletal muscle cells while having a minimal effect on proliferation.
In vivo	Cyclosporine enhances tumour growth in immunodeficient SCID-beige mice. This compound inhibits muscle regeneration after induced trauma in mice. It peaks at 1 hour in blood, spleen, and kidney, with higher concentrations in spleen and kidney than in blood.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10028970/ [2] https://pubmed.ncbi.nlm.nih.gov/10878286/ [3] https://pubmed.ncbi.nlm.nih.gov/15816878/ [4] https://pubmed.ncbi.nlm.nih.gov/9763451/ [5] https://pubmed.ncbi.nlm.nih.gov/10573076/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-31)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04877288	RECRUITING	Renal Allograft Recipients	Bristol-Myers Squibb	2021-07-21	PHASE3
NCT06013423	RECRUITING	Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematopoietic and Lymphatic System Neoplasm; Mixed Phenotype Acute Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma; Chronic Myeloid Leukemia, BCR-ABL1 Positive	Fred Hutchinson Cancer Center	2024-07-23	PHASE2
NCT05600426	ACTIVE_NOT_RECRUITING	Severe Aplastic Anemia	Boston Children's Hospital	2023-01-25	PHASE3
NCT07345000	NOT_YET_RECRUITING	Treatment-naïve Severe Aplastic Anemia	Qilu Pharmaceutical Co., Ltd.	2026-01	PHASE3
NCT07739914	NOT_YET_RECRUITING	Liver Allograft; Liver Diseases; Liver Transplantation	Hannover Medical School	2026-06-30	PHASE3
NCT01624805	RECRUITING	Aplastic Anemia; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome	M.D. Anderson Cancer Center	2012-06-25	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the difference between S2286 (it) and S1514 (this compound)?

Answer:
It is a mixture of Cyclosporine A, derivatives of Cyclosporine A, and salts of Cyclosporine A. Cyclosporine A is an especially useful component of this compound.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Cyclosporine phosphatase inhibitor

Chemical Structure

Molecular Weight: 1202.61